Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 known ✓ | P35367 | 3/20 | 0.70 |
| ▸ | DRD3 known ✓ | P35462 | 2/20 | 0.70 |
| ▸ | DRD2 known ✓ | P14416 | 1/20 | 0.70 |
| ▸ | KCNH2 known ✓ | Q12809 | 2/20 | 0.68 |
| ▸ | PDE4A known ✓ | P27815 | 1/20 | 0.68 |
| ▸ | HTR2A known ✓ | P28223 | 1/20 | 0.68 |
| ▸ | HTR2B known ✓ | P41595 | 1/20 | 0.68 |
| ▸ | PDE3A known ✓ | Q14432 | 1/20 | 0.68 |
| ▸ | CYP2J2 | P51589 | 13/20 | 0.82 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.71 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.71 |
| ▸ | CYP2B6 | P20813 | 2/20 | 0.71 |
| ▸ | LMNA | P02545 | 2/20 | 0.70 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.70 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.70 |
| ▸ | CNR1 | P21554 | 1/20 | 0.68 |
| ▸ | APEX1 | P27695 | 1/20 | 0.68 |
| ▸ | BLM | P54132 | 1/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1395734 | 0.99 | CYP2J2 (0.84) | CYP2J2CYP3A4CYP2C9CYP2B6HRH1 | |
| SCHEMBL18765452 | 0.98 | CYP2J2 (0.82) | CYP2J2CYP3A4CYP2C9CYP2B6HRH1 | |
| SCHEMBL13525525 | 0.92 | CYP2J2 (0.82) | CYP2J2CYP3A4CYP2C9CYP2B6HRH1 | |
| SCHEMBL8167710 | 0.92 | CYP2J2 (0.80) | CYP2J2CYP3A4CYP2C9CYP2B6HRH1 | |
| Hydrochloric Acid SCHEMBL11830435 | 0.92 | CYP2J2 (0.98) | CYP2J2CYP3A4CYP2C9CYP2B6HRH1 | |
| Terfenadone SCHEMBL11801242 | 0.92 | CYP2J2 (0.98) | CYP2J2CYP3A4CYP2C9CYP2B6HRH1 | |
| SCHEMBL18765451 | 0.91 | CYP2J2 (0.81) | CYP2J2CYP3A4CYP2C9CYP2B6HRH1 | |
| SCHEMBL2763954 | 0.91 | CYP2J2 (0.84) | CYP2J2CYP3A4CYP2C9CYP2B6HRH1 | |
| Terfenadone SCHEMBL11364486 | 0.90 | CYP2J2 (1.00) | CYP2J2CYP3A4CYP2C9CYP2B6HRH1 | |
| SCHEMBL11826925 | 0.90 | CYP2J2 (1.00) | CYP2J2CYP3A4CYP2C9CYP2B6HRH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2261207-A1 | Intermediates for the preparation of antihistaminic 4-diphenylmethyl/diphenylmethoxy piperidine derivatives | Aventisub II Inc. (US) | 2010-12-15 | — | — | EP | disclosed |
| EP-2261208-A1 | Intermediates for the preparation of antihistaminic 4-diphenylmethyl/diphenylmethoxy piperidine derivatives | Aventisub II Inc. (US) | 2010-12-15 | — | — | EP | disclosed |
| EP-1953142-A1 | Process for the preparation of antihistaminic 4-diphenylmethyl piperidine derivatives | Aventis Inc. (US) | 2008-08-06 | — | — | EP | disclosed |
| US-6777555-B2 | 3-(OPTIONALLY HYDROXYL)-4-(CYCLOPROPYLCARBONYL)-CUMENE INTERMEDIATE | MERRELL PHARMACEUTICALS, INC. | 2004-08-17 | — | — | US | disclosed |
| US-20030220496-A1 | Novel intermediates useful for the preparation of antihistaminic piperidine derivatives | MERRELL PHARMACEUTICALS, INC. | 2003-11-27 | — | — | US | disclosed |
| US-6566526-B2 | Intermediates useful for the preparation of antihistaminic piperidine derivatives | MERRELL PHARMACEUTICALS INC. | 2003-05-20 | — | — | US | disclosed |
| US-6559312-B2 | Cyclopropyl phenyl ketone compound | MERRELL PHARMACEUTICALS INC. | 2003-05-06 | — | — | US | disclosed |
| US-6555689-B2 | Antiallergy agents and bronchodilators | MERRELL PHARMACEUTICALS INC. | 2003-04-29 | — | — | US | disclosed |
| US-6548675-B2 | 1-Cyclopropylcarbonyl-2-hydroxy(optional),4-isopropylbenzene used as starting materials for 1-((2-hydroxy(optional),4-alkylphenyl)carbonylalkyl-),4-(diphenylmethyl -)piperidine derivatives; antihistamines; antiallergens; bronchodilators | MERRELL PHARMACEUTICALS INC. | 2003-04-15 | — | — | US | disclosed |
| US-20020198407-A1 | Novel intermediates useful for the preparation of antihistaminic piperidine derivatives | MERRELL PHARMACEUTICALS INC. | 2002-12-26 | — | — | US | disclosed |
| US-5654433-A | Process for piperidine derivatives | MERRELL PHARMACEUTICALS INC. (US) | 1997-08-05 | — | — | US | disclosed |
| US-5652370-A | Process for piperidine derivatives | MERRELL PHARMACEUTICALS INC. (US) | 1997-07-29 | — | — | US | disclosed |
| US-5650516-A | Process for piperidine derivatives | MERRELL PHARMACEUTICALS INC. (US) | 1997-07-22 | — | — | US | disclosed |
| US-5644061-A | Process for piperidine derivatives | MERRELL PHARMACEUTICALS INC. (US) | 1997-07-01 | — | — | US | disclosed |
| US-5631375-A | Process for piperidine derivatives | MERRELL PHARMACEUTICALS, INC. (US) | 1997-05-20 | — | — | US | disclosed |
| US-5618940-A | Process for piperidine derivatives | MERRELL PHARMACEUTICALS INC. (US) | 1997-04-08 | — | — | US | disclosed |
| EP-0705245-A1 | NOVEL INTERMEDIATES FOR THE PREPARATION OF ANTIHISTAMINIC 4-DIPHENYLMETHYL/DIPHENYLMETHOXY PIPERIDINE DERIVATIVES | MERRELL PHARMACEUTICALS INC. (US) | 1996-04-10 | — | — | EP | disclosed |
| EP-0635004-A1 | 4-DIPHENYLMETHYL PIPERIDINE DERIVATIVES AND PROCESS FOR THEIR PREPARATION | MERRELL PHARMACEUTICALS INC. (US) | 1995-01-25 | — | — | EP | disclosed |
| WO-1995000480-A1 | NOVEL INTERMEDIATES FOR THE PREPARATION OF ANTIHISTAMINIC 4-DIPHENYLMETHYL/DIPHENYLMETHOXY PIPERIDINE DERIVATIVES | MERRELL PHARMACEUTICALS INC. (US) | 1995-01-05 | — | — | WO | disclosed |
| WO-1993021156-A1 | 4-DIPHENYLMETHYL PIPERIDINE DERIVATIVES AND PROCESS FOR THEIR PREPARATION | MERRELL DOW PHARMACEUTICALS INC. (US) | 1993-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020198407-A1 | Novel intermediates useful for the preparation of antihistaminic piperidine derivatives | HRH1, HRH3, HRH4 | HRH1 1/4885DRD3 32/4885DRD2 80/4885 |
| US-20030220496-A1 | Novel intermediates useful for the preparation of antihistaminic piperidine derivatives | HRH1, HRH3, HRH4 | HRH1 1/4885DRD3 43/4885DRD2 93/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.